Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Incyte Corporation
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06873789CT.gov A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04989387CT.gov Study of INCA 0186 in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03910530CT.gov A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03522142CT.gov A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | — | Terminated | — | — | — |
NCT03589651CT.gov INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03406949CT.gov MGD009/MGA012 Combination in Relapsed/Refractory Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retifanlimab (this asset) | Incyte Corporation | P1/2 | CCC · 53 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Retifanlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anal Canal Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Urothelial Carcinoma | — | P2 | BB · 66 |
| Renal Cell Carcinoma | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retifanlimab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retifanlimab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →